Entresto (Sacubitril/Valsartan): Angiotensin Receptor Neprilysin Inhibition for Treating Heart Failure

AbstractPurpose of ReviewHeart failure is a major and growing public health problem throughout the world. Sacubitril/valsartan is a new medication with proven benefit in chronic heart failure with reduced ejection fraction. In order to use it most effectively, a thorough understanding of this medication is essential for providers.Recent FindingsRecent evidence demonstrates a significant improvement in mortality and heart failure hospitalizations and an acceptable side effect profile with sacubitril/valsartan in patients with heart failure and reduced ejection fraction. The most frequent adverse reaction is hypotension, which rarely necessitates discontinuation of therapy. Trials are underway for additional indications for this medication.SummarySacubitril/valsartan is a safe and efficacious treatment for heart failure with reduced ejection fraction. Whether use of sacubitril/valsartan in heart failure with preserved ejection fraction and in post-myocardial infarction left ventricular dysfunction will improve outcomes will be determined by ongoing studies.
Source: Current Emergency and Hospital Medicine Reports - Category: Emergency Medicine Source Type: research